JNJ-89402638

Phase 1Small molecule

Johnson & Johnson

JNJ-89402638 is one of 23 small molecule programs targeting Colorectal Neoplasms. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Colorectal NeoplasmsRecruiting

Colorectal NeoplasmsPhase 1

Recruiting

Competition

Competitive Landscape

23 competitors in Colorectal Neoplasms

#DrugCompanyPhaseTrials

Avastin

Roche

Phase 3

5 2

Eloxatin

Teva

Phase 3

4 3

Rybrevant

Johnson & Johnson

Phase 3

2 4

Camptosar

Pfizer

Phase 3

2 5

Camptosar

Pfizer

Phase 3

1 6

Tukysa

Pfizer

Phase 3

1 7

Wellcovorin

GGlaxo Dba Glaxosmithkline

Phase 3

2 8

5-Fluorouracil

Merck & Co.

Phase 3

4 9

Herceptin

OOrganon and Co

Phase 3

1 10

Fusilev

AActavis Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1Recruiting

Colorectal Neoplasms

NCT06663319

Clinical

Trials by Indication[1]

Colorectal Neoplasms1 trial

A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer and Other Gastrointestinal Malignancies

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT06663319·260 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for JNJ-89402638. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JNJ-89402638 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JNJ-89402638. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Johnson & Johnson

JNJ-89402638

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Colorectal Neoplasms1 trial

References

Drug Info

Quick Facts

Related News